After It Fell 58%, Wall Street Expects This EV Battery Stock to Soar 230%

monsitj / iStock via Getty Images

Rechargeable lithium-ion batteries have come a long way in the past few decades. And they make the increasing consumer electronics-driven society possible, powering everything from smartphones to electric vehicles (EVs). Demand for these batteries is expected to increase dramatically by the end of the decade. That means opportunities for investors to make some profits. One such opportunity could be Enovix Corp. (NASDAQ: ENVX), a lithium-ion battery maker based in the San Francisco area that went public in July of 2021. Its share price has tumbled since last summer, but it is projected to soar in the coming year. So what’s up here? Let’s have a look.

How Enovix Has Fared

Source: Pasha Pechenkin / iStock via Getty Images
No boost from rising demand?
Price Change Target Price Est. One-Year Gain
−58.2% $29.73 228.9%

Enovix engages in the design, development, and manufacture of silicon-anode lithium-ion batteries. It serves wearables and Internet of Things, smartphone, laptops and tablets, industrial and medical, and EV industries. The company’s proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy.

The company’s market cap is about $1.5 billion. That is less than that of competitor QuantumScape Corp. (NYSE: QS) but greater than those of FREYR Battery Inc. (NYSE: FREY) and Microvast Holdings Inc. (NASDAQ: MVST).

When Enovix released its fourth-quarter results last month, the report highlighted that revenue had surged, thanks to the completion of its acquisition of Routejade, a manufacturer of lithium-ion cells. It also pointed to its progress in scaling operations made with the build-out of Fab2 in Malaysia, establishing a strong manufacturing base and team in Malaysia.

Earlier in the year, Enovix batteries were selected for an FDA-approved accurate mini blood pressure monitor. The company also established a research and design center in India, and it named a new chief financial officer.

There was a runup in the stock ahead of the recent earnings report, but shares retreated again afterward and were last seen down more than 8%. The S&P 500 and Nasdaq are up about 8% since the beginning of the year. The stock’s 52-week high is $23.90, and the all-time high is more than $35.

So, the stock has not fared well lately. Let’s see where the share price may go from here.

Who Is Rooting for This Stock?

Source: pinstock / Getty Images
Analysts have high expectations.

Eleven analysts have price targets that range from $12 to $100, all above the current share price. Reaching the high price would be a gain of more than 1,012% for the stock. Not surprisingly, the consensus recommendation is to buy shares. The three most recent analyst calls, from late February, reiterated Buy ratings.

Will the stock recover and soar this year? Almost all of the analysts who cover the stock have high expectations.


ALERT: Take This Retirement Quiz Now  (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.